Abstract
Objective: The aim of this study was to evaluate the efficacy of olanzapine in girls with anorexia nervosa, restricting subtype (ANr). Methods: Thirteen patients (mean age 13.7±2.3 years, age range 9.6-16.3 years) enrolled in a multimodal treatment for ANr were evaluated with standardized measures at baseline and after 1 and 6 months after starting low-dose olanzapine monotherapy (mean dose 4.13mg/day). Results: A significant improvement was evident on weight (body mass index, BMI), global functioning (Children's Global Assessment Scale, CGAS), eating attitudes (Eating Attitudes Test-26, EAT-26), anxious-depressive symptoms (Child Behavior Checklist, CBCL) and hyperactivity (Structured Inventory for Anorexic and Bulimic Syndromes, SIAB). At the end of the 6-month follow up, 7 patients were responders according to an improvement of at least 50% in the EAT-26 results. The only measure that improved significantly in responders, but not in nonresponders, was hyperactivity (SIAB). Clinical improvement, in terms of both body mass index (BMI) recovery and global functioning, paralleled the improvement of hyperactivity, was evident at the end of the first month of treatment, and further increased in the following 5 months, with minimal side effects. Conclusions: Low-dose olanzapine monotherapy may be useful as adjunctive treatment of youths with ANr. It is suggested that efficacy may be mediated by a decrease of hyperactivity.
| Original language | English |
|---|---|
| Pages (from-to) | 127-133 |
| Number of pages | 7 |
| Journal | Journal of Child and Adolescent Psychopharmacology |
| Volume | 20 |
| Issue number | 2 |
| DOIs | |
| Publication status | Published - Apr 1 2010 |
Fingerprint
ASJC Scopus subject areas
- Pediatrics, Perinatology, and Child Health
- Pharmacology (medical)
- Psychiatry and Mental health
Cite this
Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype : Focus on hyperactivity. / Leggero, Chiara; Masi, Gabriele; Brunori, Elena; Calderoni, Sara; Carissimo, Renato; Maestro, Sandra; Muratori, Filippo.
In: Journal of Child and Adolescent Psychopharmacology, Vol. 20, No. 2, 01.04.2010, p. 127-133.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Low-dose olanzapine monotherapy in girls with anorexia nervosa, restricting subtype
T2 - Focus on hyperactivity
AU - Leggero, Chiara
AU - Masi, Gabriele
AU - Brunori, Elena
AU - Calderoni, Sara
AU - Carissimo, Renato
AU - Maestro, Sandra
AU - Muratori, Filippo
PY - 2010/4/1
Y1 - 2010/4/1
N2 - Objective: The aim of this study was to evaluate the efficacy of olanzapine in girls with anorexia nervosa, restricting subtype (ANr). Methods: Thirteen patients (mean age 13.7±2.3 years, age range 9.6-16.3 years) enrolled in a multimodal treatment for ANr were evaluated with standardized measures at baseline and after 1 and 6 months after starting low-dose olanzapine monotherapy (mean dose 4.13mg/day). Results: A significant improvement was evident on weight (body mass index, BMI), global functioning (Children's Global Assessment Scale, CGAS), eating attitudes (Eating Attitudes Test-26, EAT-26), anxious-depressive symptoms (Child Behavior Checklist, CBCL) and hyperactivity (Structured Inventory for Anorexic and Bulimic Syndromes, SIAB). At the end of the 6-month follow up, 7 patients were responders according to an improvement of at least 50% in the EAT-26 results. The only measure that improved significantly in responders, but not in nonresponders, was hyperactivity (SIAB). Clinical improvement, in terms of both body mass index (BMI) recovery and global functioning, paralleled the improvement of hyperactivity, was evident at the end of the first month of treatment, and further increased in the following 5 months, with minimal side effects. Conclusions: Low-dose olanzapine monotherapy may be useful as adjunctive treatment of youths with ANr. It is suggested that efficacy may be mediated by a decrease of hyperactivity.
AB - Objective: The aim of this study was to evaluate the efficacy of olanzapine in girls with anorexia nervosa, restricting subtype (ANr). Methods: Thirteen patients (mean age 13.7±2.3 years, age range 9.6-16.3 years) enrolled in a multimodal treatment for ANr were evaluated with standardized measures at baseline and after 1 and 6 months after starting low-dose olanzapine monotherapy (mean dose 4.13mg/day). Results: A significant improvement was evident on weight (body mass index, BMI), global functioning (Children's Global Assessment Scale, CGAS), eating attitudes (Eating Attitudes Test-26, EAT-26), anxious-depressive symptoms (Child Behavior Checklist, CBCL) and hyperactivity (Structured Inventory for Anorexic and Bulimic Syndromes, SIAB). At the end of the 6-month follow up, 7 patients were responders according to an improvement of at least 50% in the EAT-26 results. The only measure that improved significantly in responders, but not in nonresponders, was hyperactivity (SIAB). Clinical improvement, in terms of both body mass index (BMI) recovery and global functioning, paralleled the improvement of hyperactivity, was evident at the end of the first month of treatment, and further increased in the following 5 months, with minimal side effects. Conclusions: Low-dose olanzapine monotherapy may be useful as adjunctive treatment of youths with ANr. It is suggested that efficacy may be mediated by a decrease of hyperactivity.
UR - http://www.scopus.com/inward/record.url?scp=77951693368&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=77951693368&partnerID=8YFLogxK
U2 - 10.1089/cap.2009.0072
DO - 10.1089/cap.2009.0072
M3 - Article
VL - 20
SP - 127
EP - 133
JO - Journal of Child and Adolescent Psychopharmacology
JF - Journal of Child and Adolescent Psychopharmacology
SN - 1044-5463
IS - 2
ER -